Answers are grounded in this paper and cite their sources.
To the Editor: The rapid rate of HIV-1 replication in vivo(109 virions per day), coupled with the poor fidelity of reverse transcription of the HIV-1 genome, results in the production of new virus variants(1). This makes it easy to understand how multiple clades of HIV-1 have emerged throughout the world and explains the development of genetic diversity even within clades(2). Numerous reports describe assays designed for the detection or quantification of HIV-1 genomic RNA in plasma. One such assay is based on a coupled reverse transcription-polymerase chain reaction (RT-PCR) process in which specific oligonucleotides sequence primers are used in conjunction with enzymes to amplify the number of HIV-1 genomes in a specimen(3). Another approach involves the nucleic acid sequence-based amplification (NASBA) procedure, which is founded on isothermal amplification of an HIV-1 RNA target sequence by simultaneous enzymatic activity of three enzymes(4). A third procedure involves direct detection of the genomic nucleic sequences by a series of signal amplification processes using a technology called branched DNA (bDNA)(5). These assay methods have been developed into commercial kits (RT-PCR: Amplicor Monitor by Roche Diagnostics Systems, Neuilly, France; NASBA: HIV-1 RNA QT assay by Organon Teknika, Fresnes, France; bDNA: Quantiplex HIV-1 RNA by Chiron Corporation, Cergy Pontoise, France) and are being used more frequently in the routine clinical management of patients infected with HIV-1.TABLE 1: Effect of the HIV-1 clade on quantitation of HIV-1 RNA by RT-PCR, bDNA, and NASBATo assess the impact of genetic variability on HIV-1 RNA quantification, we evaluated these commercial kits by using a panel of HIV-1 isolates representing clades A to H. Group O HIV-1 strains were not tested, because the different assays are exclusively recommended for quantitation of RNA for group M HIV-1 strains. These isolates were expanded in culture. Virus was collected by ultracentrifugation and resuspended in HIV-seronegative plasma. To standardize the quantities of virus to similar levels in each preparation, the p24 antigen was determined(Coultronics, Margency, France) and the volume adjusted so that each specimen contained approximately 10 pg of p24 antigen per ml. HIV-1 RNA was quantitated by the three assays according to the manufacturers instructions. Each specimen was tested in duplicate by each procedure, and results were expressed as the mean value. Results obtained by the two determinations were concordant (i.e., log difference <0.5 log) for all specimens. As presented in Table 1, disparate results were obtained according to the strains tested. We observed that clade A strains were not detected by RT-PCR and that clade G-strains were not detected by NASBA. However, the copy number detected by RT-PCR in one clade E (CM235) and in one clade F (163.3070) was much lower than the copy number detected by bDNA and NASBA (log difference >0.5). All the HIV-1 clades could be detected and quantitated by bDNA, although for clades B and D (UG270), the HIV-1 RNA levels measured by bDNA were lower than those obtained by RT-PCR and NASBA. These results demonstrate that quantification of HIV-1 RNA is highly influenced by the HIV-1 genome sequence. The level of detection of clade A strains by the Amplicor qualitative and quantitative assays has been previously reported(6,7). Our results confirm these findings and indicate that the NASBA procedure is also influenced by the HIV-1 genomic diversity. In contrast, HIV-1 RNA quantification with the Quantiplex bDNA assay demonstrated minor influence by genetic variability, presumably because of the large number of probe sequences designed into the assay(5). All three tests can be used for the quantification of RNA from clade B HIV-1 strains, which are predominant in European and American countries. However, in the case of an HIV-1 RNA level lower than the detection limit obtained with RT-PCR or NASBA in an untreated, HIV-1-infected patient, the clinician should consider verifying the RNA level by another procedure; this observation should also lead to the characterization of the HIV-1 clade. *Joliette Coste †Brigitte Montes ‡Jacques Reynes §Martine Peeters *Christiane Segarra §Eric Delaporte ‡Michel Segondy *Establishment de Transfusion Sanguine Languedoc-Roussillon †Laboratoire de Virologie ‡Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire §Laboratoire des Rétrovirus ORSTOM Montpellier, France
No takes yet. Share an insight, caveat, or question.
A 1997 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: